Derivation and Validation of an Optimal Neutrophil Gelatinase-Associated Lipocalin Cutoff to Predict Stage 2/3 Acute Kidney Injury (AKI) in Critically Ill Children

• Published in: Kidney international reports Vol. 9; no. 8; pp. 2443 - 2452
• Main Authors: Goldstein, Stuart L., Akcan-Arikan, Ayse, Afonso, Natasha, Askenazi, David J., Basalely, Abby M., Basu, Rajit K., Beng, Hostensia, Fitzgerald, Julie C., Gist, Katja, Kizilbash, Sarah, Kwiatkowski, David, Mastropietro, Christopher W., Menon, Shina, SooHoo, Megan, Traum, Avram Z., Bird, Christopher A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2024; Elsevier
• Subjects: acute kidney injury; children; neutrophil gelatinase-associated lipocalin; NGAL; NGAL; acute kidney injury; children; neutrophil gelatinase-associated lipocalin
• ISSN: 2468-0249; 2468-0249
• DOI: 10.1016/j.ekir.2024.05.010

Acute kidney injury (AKI) defined by changes in serum creatinine (SCr), or oliguria is associated with increased morbidity and mortality in children who are critically ill. We derived and validated a clinical cutoff value for urine neutrophil gelatinase-associated lipocalin (NGAL), in a prospective multicenter study of children who were critically ill. We report the clinical performance of urine NGAL (uNGAL) to aid in pediatric AKI risk assessment. Eligible subjects were aged ≥ 90 days to < 22 years, admitted to an intensive care unit (ICU), and had 1 or more of the following: mechanical ventilation, vasoactive medication administration, solid organ or bone marrow transplantation, or hypotension within 24-hours of admission. uNGAL was assessed within 24-hours of admission. The primary outcome was SCr-based stage 2/3 AKI presence at 48- to 72-hours. Twenty-five (12.3%) derivation study patients had stage 2/3 AKI at 48- to 72-hours. uNGAL concentration of 125 ng/ml was the optimal cutoff. Forty-seven (9.1%) validation study patients had stage 2/3 AKI at 48- to 72-hours. The area under the curve of a receiver operator characteristics curve (AUC-ROC) for uNGAL performance was 0.83 (95% confidence interval [CI]: 0.77–0.90). Performance characteristics were sensitivity 72.3% (95% CI: 57.4%–84.4%), specificity 86.3% (95% CI: 82.8%–89.3%), positive predictive value 34.7% (95% CI: 28.5%–41.5%), and negative predictive value 96.9% (95% CI: 95.1%–98.0%). These prospective, pediatric, multicenter studies demonstrate that uNGAL in the first 24-hours performs very well to predict Kidney Disease Improving Global Outcomes (KDIGO) stage 2/3 AKI at 48- to 72-hours into an ICU course. We suggest that a uNGAL cut point of 125 ng/ml can aid in the risk assessment for stage 2/3 AKI persistence or development. [Display omitted]